Your browser is no longer supported. Please, upgrade your browser.
Settings
CFRX ContraFect Corporation daily Stock Chart
CFRX [NASD]
ContraFect Corporation
Index- P/E24.95 EPS (ttm)0.44 Insider Own0.30% Shs Outstand15.14M Perf Week32.61%
Market Cap166.24M Forward P/E- EPS next Y-2.96 Insider Trans- Shs Float12.90M Perf Month-3.26%
Income3.50M PEG- EPS next Q-0.84 Inst Own38.10% Short Float0.25% Perf Quarter225.53%
Sales- P/S- EPS this Y-77.50% Inst Trans139.52% Short Ratio0.14 Perf Half Y183.21%
Book/sh0.53 P/B20.72 EPS next Y-133.10% ROA13.80% Target Price17.50 Perf Year148.36%
Cash/sh0.69 P/C15.83 EPS next 5Y- ROE38.40% 52W Range2.69 - 13.40 Perf YTD76.90%
Dividend- P/FCF- EPS past 5Y16.60% ROI- 52W High-18.05% Beta0.92
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin- 52W Low307.72% ATR1.27
Employees20 Current Ratio1.70 Sales Q/Q- Oper. Margin- RSI (14)64.86 Volatility16.28% 14.17%
OptionableNo Debt/Eq0.00 EPS Q/Q-19.40% Profit Margin- Rel Volume1.55 Prev Close10.84
ShortableYes LT Debt/Eq0.00 EarningsMar 12 Payout0.00% Avg Volume237.02K Price10.98
Recom1.50 SMA2023.65% SMA5041.65% SMA200121.14% Volume367,421 Change1.29%
Jul-28-16Initiated Piper Jaffray Overweight
Jul-22-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Maxim Group Buy $8 → $7
Dec-31-15Reiterated Maxim Group Buy $16 → $9
Feb-18-20 03:45PM  CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway Zacks Small Cap Research +17.34%
03:10PM  CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway Zacks Small Cap Research
11:25AM  CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway Zacks Small Cap Research
Feb-04-20 07:00AM  ContraFect Announces One-for-Ten Reverse Stock Split GlobeNewswire +6.85%
Feb-03-20 07:00AM  ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology GlobeNewswire -12.05%
Jan-27-20 07:00AM  ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GlobeNewswire -9.09%
Jan-22-20 07:00AM  ContraFect to Present at 2020 ASM Biothreats GlobeNewswire
Jan-21-20 05:00AM  CFRX: Phase 3 DISRUPT Trial Underway Zacks Small Cap Research +7.69%
Jan-13-20 08:00AM  ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections GlobeNewswire +13.33%
Jan-10-20 07:00AM  ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis GlobeNewswire +20.84%
Jan-06-20 05:30PM  ContraFect to Present at Biotech Showcase 2020 GlobeNewswire +34.38%
Jan-04-20 07:30AM  Pfizer Bought a Penny Biotech Stock Just Before It Doubled Barrons.com
Dec-20-19 10:56AM  Were Hedge Funds Right About Dumping ContraFect Corp (CFRX)? Insider Monkey -6.18%
08:00AM  ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis GlobeNewswire
Dec-18-19 07:00AM  ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa GlobeNewswire +10.54%
Dec-17-19 09:25AM  ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock GlobeNewswire -20.95%
Dec-16-19 07:30AM  NexImmune Appoints Sol Barer as Chairman of the Board of Directors GlobeNewswire +19.77%
06:40AM  CFRX: Financing Raises $12 Million, including $3 Million from Pfizer Zacks Small Cap Research
Dec-10-19 08:46AM  ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer GlobeNewswire +10.22%
07:56AM  The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
Dec-09-19 04:03PM  ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc. GlobeNewswire -8.53%
Nov-29-19 09:00AM  ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-18-19 08:05AM  CFRX: Phase 3 Trial for Exebacase in MRSA Patients Underway Soon Zacks Small Cap Research +9.72%
Nov-12-19 07:00AM  ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Nov-05-19 07:00AM  ContraFect to Present at the World Anti-Microbial Resistance Congress 2019 GlobeNewswire +6.78%
Oct-07-19 09:05AM  CFRX: Planning to Initiate Phase 3 Superiority Trial for Exebacase in 4Q19... Zacks Small Cap Research
Oct-02-19 07:00AM  ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA GlobeNewswire
Oct-01-19 05:29PM  ContraFect to Host Development Update Call and Webcast on October 2, 2019 GlobeNewswire
Sep-26-19 07:00AM  ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019 GlobeNewswire +6.47%
Sep-04-19 05:07PM  ContraFect to Present at the 2019 Janney Healthcare Conference GlobeNewswire +19.82%
Aug-28-19 07:00AM  ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance GlobeNewswire -6.95%
Aug-16-19 10:45AM  CFRX: Ready to Meet with the FDA Regarding Phase 3 Plan for Exebacase Zacks Small Cap Research
Aug-09-19 07:00AM  ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-01-19 09:13AM  X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire
Jun-20-19 11:13AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 PR Newswire
Jun-19-19 01:08PM  Investors Who Bought ContraFect (NASDAQ:CFRX) Shares Three Years Ago Are Now Down 84% Simply Wall St.
Jun-17-19 05:00PM  ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data GlobeNewswire
Jun-07-19 09:27AM  Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections PR Newswire -6.65%
Jun-06-19 07:00AM  ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296 GlobeNewswire +11.65%
Jun-03-19 07:00AM  ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium GlobeNewswire
May-31-19 07:00AM  ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal GlobeNewswire
May-20-19 10:15AM  CFRX: R&D Symposium Highlights Positive Data for Exebacase Zacks Small Cap Research -7.53%
May-10-19 07:19AM  ContraFect: 1Q Earnings Snapshot Associated Press
07:00AM  ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-08-19 07:00AM  ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease GlobeNewswire
Apr-30-19 10:30AM  CFRX: Additional Phase 2 Data Presented at ECCMID Zacks Small Cap Research
Apr-16-19 05:15AM  ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GlobeNewswire -12.64%
Apr-13-19 09:38AM  The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs Benzinga
Apr-12-19 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-08-19 07:00AM  ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal GlobeNewswire
Apr-04-19 07:00AM  ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GlobeNewswire +23.08%
Apr-02-19 07:00AM  ContraFect Announces CEO Transition GlobeNewswire
Mar-21-19 07:00AM  ContraFect to Present at the Bacteriophage Therapy Summit GlobeNewswire
Mar-20-19 10:30AM  CFRX: Planning for Phase 3 Trial of Exebacase in S. Aureus Bacteremia Zacks Small Cap Research +27.78%
Mar-14-19 08:01AM  ContraFect: 4Q Earnings Snapshot Associated Press
07:00AM  ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-13-19 07:00AM  ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference GlobeNewswire
Mar-04-19 07:00AM  ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens GlobeNewswire
Feb-25-19 07:00AM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors (CFRX) GlobeNewswire
Feb-13-19 07:00AM  ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine GlobeNewswire
Jan-17-19 10:00AM  Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire -5.80%
09:26AM  These 4 Healthcare Stocks Are Raising Expectations ACCESSWIRE
07:00AM  ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program GlobeNewswire
Jan-09-19 09:45AM  CFRX: Exebacase Improves Clinical Outcomes in Phase 2 Trial Zacks Small Cap Research -8.35%
Jan-07-19 07:00AM  ContraFects Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study GlobeNewswire -54.95%
Dec-23-18 10:22AM  Is ContraFect Corp (CFRX) A Good Stock To Buy? Insider Monkey
Dec-20-18 05:00PM  ContraFect to Present at Biotech Showcase 2019 GlobeNewswire
Nov-19-18 07:00AM  ContraFect to Present at Piper Jaffray Health Care Conference GlobeNewswire
Nov-16-18 07:50AM  Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Nov-12-18 09:15AM  CFRX: Waiting on Data from Phase 2 Study of CF-301 Zacks Small Cap Research
07:00AM  ContraFect Appoints Michael Messinger as Chief Financial Officer GlobeNewswire
Nov-08-18 09:59AM  ContraFect: 3Q Earnings Snapshot Associated Press +7.69%
07:00AM  ContraFect Announces Third Quarter 2018 Financial Results GlobeNewswire
Nov-01-18 07:00AM  ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes GlobeNewswire
Oct-22-18 05:00PM  ContraFect to Participate in World Antimicrobial Resistance Congress 2018 GlobeNewswire
Sep-25-18 07:00AM  ContraFect to Present at the Exploring the Antibiotic Pipeline 2018 Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018 GlobeNewswire +5.52%
Sep-24-18 09:30AM  CFRX: Enrollment for Phase 2 Trial of CF-301 Complete; Data in 4Q18 Zacks Small Cap Research +11.73%
Sep-20-18 05:00PM  ContraFect to Present at Two Upcoming Investor Conferences GlobeNewswire
Sep-06-18 08:30AM  ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia GlobeNewswire
Aug-29-18 05:30PM  ContraFect to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-14-18 05:00PM  ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections GlobeNewswire
Aug-13-18 12:15PM  CFRX: Data from Phase 2 Trial of CF-301 in 4Q18 Zacks Small Cap Research
Aug-09-18 07:35AM  ContraFect: 2Q Earnings Snapshot Associated Press
07:00AM  ContraFect Announces Second Quarter 2018 Financial Results GlobeNewswire
Jul-27-18 09:00AM  ContraFect Corporation Prices $10 Million Public Offering of Common Stock GlobeNewswire -11.42%
Jul-26-18 04:12PM  ContraFect Corporation Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-18-18 10:00AM  CFRX: Developing Gram-Negative Lysin Targeting P. aeruginosa Zacks Small Cap Research +8.97%
Jun-14-18 07:00AM  ContraFect to Present at JMP Securities Life Sciences Conference GlobeNewswire +6.95%
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire
Jun-05-18 04:47PM  Lysins plus antibiotics: A cure for human bacterial infections? Reuters Videos
Jun-01-18 09:17PM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors (CFRX) Business Wire
May-30-18 07:00AM  ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018 GlobeNewswire
May-14-18 11:50AM  CFRX: Multiple Presentations on CF-301 at ECCMID Zacks Small Cap Research
May-10-18 07:58AM  ContraFect: 1Q Earnings Snapshot Associated Press
07:00AM  ContraFect Announces First Quarter 2018 Financial Results GlobeNewswire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-11-18 09:00AM  ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GlobeNewswire
Mar-27-18 03:04PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of ContraFect Corporation Investors (CFRX) Business Wire
07:00AM  Free Post Earnings Research Report: Incytes Quarterly Sales 36% Surged ACCESSWIRE
Mar-21-18 11:30AM  CFRX: No Safety Issues Noted Thus Far in Phase 2 Trial of CF-301 Zacks Small Cap Research
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Messinger MichaelChief Financial OfficerDec 13Buy0.375,0001,85019,091Dec 16 06:28 AM
Sucoff CaryDirectorDec 13Buy0.3950,00019,50062,000Dec 16 06:26 AM
Low David N.DirectorDec 13Buy0.43300,000129,000370,550Dec 16 06:21 AM